UltraGreen.ai invests $12.3m in LifeSignals, IHLD

The investments were funded from IPO proceeds and are not expected to materially affect FY2026 EPS.

UltraGreen.ai has used $12.3m (US$7.5m) of its initial public offering proceeds for convertible loans to LifeSignals Group and IHLD Med Tech as part of its strategic growth initiatives.

The company invested $5.8m (US$4.5m) in LifeSignals to support biosensor manufacturing, software enhancements, and working capital requirements.

LifeSignals’ biosensors are distributed internationally through UltraGreen.ai’s subsidiary, UltraGreen Data Systems.

The collaboration will support commercialisation under a new brand, UltraGreen Cardiac Technologies, which will represent the group’s cardiology distribution business.

UltraGreen.ai said the partnership is expected to contribute revenue through the sale and distribution of LifeSignals Holter devices, with an initial focus on the US and Europe.

LifeSignals is an associate of Renew Group, a controlling shareholder of UltraGreen.ai. The investment is therefore an interested person transaction, but does not require shareholders’ approval as it does not reach the relevant threshold under Chapter 9 of the Listing Manual.

UltraGreen.ai also invested $3.8m (US$3m) in IHLD Med Tech through a convertible loan to expand its fluorescence-guided platform into India’s wound care market. The investment may increase to up to $15.4m (US$12m), subject to agreed milestones.

The IHLD initiative will initially focus on wound care across cardiac, diabetic, trauma, and other clinical applications. Go-to-market activities are expected to begin in the next two to three months.

UltraGreen.ai said the LifeSignals and IHLD transactions are not expected to have any material impact on the group’s earnings per share for the financial year ending 31 December 2026.

Including $1.9m (US$1.5m) used for working capital and general corporate purposes, UltraGreen.ai has used $11.5m (US$9.0m) of its IPO proceeds, leaving a balance of $171.8m (US$134.1m). The company said the utilisation is in line with the intended use set out in its prospectus.

($1 = US$0.78)

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia